biomedicina slovenica

"Clinical trials, phase III" : 16

  1. Kocjan Andrej; Jerebic Luka; Šeruga Boštjan
    Varnost in učinkovitost tarčnih zdravil pri bolnikih z napredovalim rakom ledvice v vsakodnevni klinični praksi
    2015 ►
  2. Šeruga Boštjan; Tannock Ian
    Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
    2008 ►
  3. Šeruga Boštjan; Sterling Lynn; Wang Lisa; Tannock Ian
    Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs)
    2010 ►
  4. Šeruga Boštjan; Hertz Paul C.; Wang Lisa; Booth C. M.; Krzyzanowska M. K.; Cescon David W.; Tannock Ian
    Absolute benefits of experimental medical therapies in phase III randomized clinical trials (RCTs) in breast and colorectal cancer
    2009 ►
  5. Šeruga Boštjan
    Klinično preizkušanje novih vrst zdravljenja v onkologiji - zahtevajmo več!
    [Clinical trials of new types of treatment in oncology - demand more!]
    2012 ►
  6. Regan Meredith; Neven Patrick; Giobbie-Hurder Anita; Čufer T
    Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8-1 years median follow-up
    2011 ►
  7. von Minckwitz Gunter; Schwedler Kathrin; Schmidt Marcus; Čufer Tanja
    Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
    2011 ►
  8. Bonnefoi Herve; Piccart Martine; Bogaerts Jan; Čufer Tanja
    TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
    2011 ►
  9. Regan MM; Price KN; Giobbie-Hurder A; Thuerliman B; Gelber RD; Čufer T; Pajk B; Červek J
    Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
    2011 ►
  10. Šeruga Boštjan; Sterling Lynn; Wang Lisa; Tannock Ian
    Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials
    2010 ►
  11. Aleman Berthe M. P.; Tomšič Radka
    Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma
    2007 ►
  12. Morales Leilani; Čufer Tanja
    Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer : a randomised phase III trial of the European Organis[!]ation for Research and Treatment of Cancer Breast Group
    2007 ►
  13. Irgolič Nada
    Pregled predpisov, ki urejajo področje prometa s krvjo in zdravil iz krvi
    2000 ►
  14. Zwitter Matjaž
    Communicatin with the patient in clinical research
    2000 ►
  15. Therasse P; Mauriac L; Welnicka M; Bruning P; Čufer T; Lichinitser R; Pluzanska A; Tomiak E; Koopmanschap M; Piccart M
    The added value of the combined evaluation of clinical efficacy, quality of life and cost-effectiveness in a randomized phase III study: results of an EORTC-NCIC-SAKK neoadjuvant trial in patients with locally advanced breast cancer (LABC)
    1999 ►
  16. Zwitter Matjaž
    Etična vprašanja kliničnega raziskovanja v onkologiji
    1998 ►


New search      Comments      Top of page Institute for Biostatistics and Medical Informatics